EcoDrugPlus

Proteasome 20s Subunit Alpha 5

Ensembl ID : ENSLBEG00000011899
Gene Symbol: PSMA5
3 Cross references
211 Possible Orthologues:

Proteasome 20s Subunit Alpha 6

Ensembl ID : ENSLBEG00000021929
Gene Symbol: PSMA6
3 Cross references
244 Possible Orthologues:

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSLBEG00000018353
Gene Symbol: PSMA8
3 Cross references
182 Possible Orthologues:

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSLBEG00000003033
Gene Symbol: PSMB1
3 Cross references
217 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSLBEG00000010835
Gene Symbol: PSMB2
3 Cross references
219 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSLBEG00000016607
Gene Symbol: PSMB3
3 Cross references
260 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSLBEG00000023209
Gene Symbol: PSMB4
3 Cross references
214 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSLBEG00000023359
Gene Symbol: PSMB7
3 Cross references
216 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSLBEG00000005502
Gene Symbol: PSMC1
3 Cross references
285 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSLBEG00000026765
Gene Symbol: PSMC2
3 Cross references
232 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSLBEG00000003008
Gene Symbol: PSMC3
3 Cross references
226 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSLBEG00000024231
Gene Symbol: PSMC4
3 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).